CERS - Cerus Corporation reports Q4 preliminary results

Cerus Corporation ([[CERS]] +0.5%) reports Q4 preliminary sales of $28.2M vs. consensus of $28.16M, an increase of 35% Y/Y representing the highest quarterly product revenue ever reported by Cerus, further taking the full year 2020 sales to $91.9M, exceeding the Company’s current 2020 product guidance range of $89M-91M.FY 2021 guidance: Sales in the range of $106M-110M vs. consensus of $118.4M, representing growth of ~15% to 20% compared to preliminary unaudited 2020 full year results, mainly driven by strong platelet kit demand in the U.S., as well as expected continued market adoption in targeted international markets.The company expects to release its full Q4 results in late Feb. 2021.

For further details see:

Cerus Corporation reports Q4 preliminary results